Dilaudid PCA

PreclinicalSmall molecule

TTriHealth Inc.

Dilaudid PCA is one of 4 small molecule programs targeting Patient Satisfaction. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Patient SatisfactionCompleted

Patient SatisfactionPreclinical

Completed

Competition

Competitive Landscape

4 competitors in Patient Satisfaction

#DrugCompanyPhaseTrials

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Approved

2 2

Kybella

AbbVie

Phase 3

1 3

Dilaudid PCA

TTriHealth Inc.

Preclinical

1 4

Self Assembling Peptide

NNahda University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Patient Satisfaction1 trial

Patient Satisfaction and Pain Control Following Reconstructive Vaginal Surgery

Completed·TTriHealth Inc.·N/A·NCT01442818·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dilaudid PCA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dilaudid PCA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dilaudid PCA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TriHealth Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TTriHealth Inc.

Dilaudid PCA

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Patient Satisfaction1 trial

References

Drug Info

Quick Facts

Related News